- Home
- NRXP vs WAI Comparison
NRXP vs WAI Comparison
Compare NRXP & WAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- WAI
- Stock Information
- Founded
- NRXP 2015
- WAI 2018
- Country
- NRXP United States
- WAI China
- Employees
- NRXP N/A
- WAI N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- WAI
- Sector
- NRXP Health Care
- WAI
- Exchange
- NRXP Nasdaq
- WAI NYSE
- Market Cap
- NRXP 34.7M
- WAI 28.2M
- IPO Year
- NRXP N/A
- WAI 2023
- Fundamental
- Price
- NRXP $1.98
- WAI $0.16
- Analyst Decision
- NRXP Strong Buy
- WAI
- Analyst Count
- NRXP 4
- WAI 0
- Target Price
- NRXP $28.25
- WAI N/A
- AVG Volume (30 Days)
- NRXP 128.2K
- WAI 112.5K
- Earning Date
- NRXP 05-13-2025
- WAI 05-24-2025
- Dividend Yield
- NRXP N/A
- WAI N/A
- EPS Growth
- NRXP N/A
- WAI N/A
- EPS
- NRXP N/A
- WAI N/A
- Revenue
- NRXP N/A
- WAI $3,750,352.00
- Revenue This Year
- NRXP N/A
- WAI N/A
- Revenue Next Year
- NRXP N/A
- WAI N/A
- P/E Ratio
- NRXP N/A
- WAI N/A
- Revenue Growth
- NRXP N/A
- WAI N/A
- 52 Week Low
- NRXP $1.10
- WAI $0.10
- 52 Week High
- NRXP $6.01
- WAI $1.29
- Technical
- Relative Strength Index (RSI)
- NRXP 48.76
- WAI N/A
- Support Level
- NRXP $1.85
- WAI N/A
- Resistance Level
- NRXP $1.97
- WAI N/A
- Average True Range (ATR)
- NRXP 0.16
- WAI 0.00
- MACD
- NRXP 0.03
- WAI 0.00
- Stochastic Oscillator
- NRXP 71.43
- WAI 0.00
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About WAI TOP KINGWIN LTD
Top KingWin Ltd operates as a corporate business training and consulting company, providing personal and management training and financial consulting services. It provides a number of essential business services in China to young and emerging companies including corporate business training services, which mainly focus on advanced knowledge and new perspectives on the capital markets; corporate consulting services, which mainly focus on various aspects of fundraising, and advisory and transaction services. Its main clients are entrepreneurs and executives in China's small and medium enterprises (SMEs).